Chilean Multidisciplinary Consensus on the Use of GLP-1 Receptor Agonists: Recommendations Based on the GRADE Methodology

Type 2 diabetes (T2DM), obesity, chronic kidney disease (CKD), and heart failure (HF) pose a major public health burden in Chile and Latin America. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide glycemic, cardiovascular, renal, and weight-loss benefits, extending their therapeutic role beyond glycemic control.

Aim

To develop a national consensus, based on GRADE methodology, that synthesizes the best available evidence and adapts it to the Chilean healthcare context, providing practical recommendations for the rational use of GLP-1 RA (GLP-1 receptor agonists).